Rallybio (NASDAQ:RLYB – Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.
Profitability
This table compares Rallybio and NewAmsterdam Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rallybio | -911.07% | -40.53% | -38.13% |
| NewAmsterdam Pharma | -3,644.21% | -34.81% | -31.50% |
Institutional & Insider Ownership
90.3% of Rallybio shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Rallybio and NewAmsterdam Pharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rallybio | $646,000.00 | 137.87 | -$8.98 million | ($4.34) | -3.86 |
| NewAmsterdam Pharma | $7.12 million | 346.14 | -$203.82 million | ($2.16) | -9.55 |
Rallybio has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings for Rallybio and NewAmsterdam Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rallybio | 0 | 1 | 0 | 0 | 2.00 |
| NewAmsterdam Pharma | 1 | 1 | 10 | 1 | 2.85 |
NewAmsterdam Pharma has a consensus target price of $49.00, suggesting a potential upside of 137.63%. Given NewAmsterdam Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Rallybio.
Volatility and Risk
Rallybio has a beta of -0.72, meaning that its stock price is 172% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500.
Summary
NewAmsterdam Pharma beats Rallybio on 11 of the 15 factors compared between the two stocks.
About Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
